Top 20 Companies in the Global Biopharmaceutical CMO and CRO Market: Global Share, Market Size, Revenue Report (2024–2035)
RELEASE DATE: Mar 2026 Author: Spherical InsightsRequest Free Sample Speak to Analyst
Introduction
The biopharmaceutical industry needs more productivity because its main companies are increasing their research investments. Bio manufacturers are now directing their efforts towards outsourcing because of the growing need for biopharmaceutical companies to improve their manufacturing processes. Biopharma companies now choose to outsource their whole biomanufacturing operations, which include both resource-intensive and capital-intensive activities. The biopharmaceutical industry has experienced growth because more companies choose to use contract services, which help them improve their outsourced operations. For example, in February 2024, Thermo Fisher Scientific expanded its GMP Laboratory Services at its Middleton, Wisconsin, location to include state-of-the-art biosafety testing solutions such as mycoplasma testing and qPCR-based analytical solutions, as well as enhanced contamination control solutions. This expansion has strengthened its analytical solutions portfolio in biopharmaceutical development through faster and more accurate testing solutions, which can help in cell and gene therapy development as well as product safety and compliance.
The biosimilars and biologics markets require specialised manufacturing skills, which many companies do not have. The expansion of new markets, especially in Asia, will attract more customers who need high-quality biopharmaceutical services. AbbVie expanded its biologics manufacturing capacity at its Singapore Tuas facility through a US 223 million investment, which helped to increase drug-substance production capacity by 24000 liters. The expansion provides support for existing and future immunology and oncology biologics while creating more than 100 specialised positions that demonstrate how international biopharmaceutical companies are establishing partnerships with Asian manufacturing facilities to access top-notch production capabilities that they lack internally.
Navigate Future Markets with Confidence: Insights from Spherical Insights LLP
The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Biopharmaceutical CMO and CRO Market
Biopharmaceutical CMO and CRO Market Size & Statistics
- The Market Size for Biopharmaceutical CMO and CRO Was Estimated to be worth USD 39.1 Billion in 2024.
- The Market Size is Going to Expand at a CAGR of 6.1% between 2025 and 2035.
- The Global Biopharmaceutical CMO and CRO Market Size is anticipated to reach USD 74.99 Billion by 2035.
- North America is estimated to dominate the market during the forecast period in the Biopharmaceutical CMO and CRO Market.
- Asia-Pacific is projected to grow the fastest during the forecast period in the Biopharmaceutical CMO and CRO Market.
Market Segmentation
Global Biopharmaceutical CMO and CRO Market Size, Share, By Source (Mammalian and Non-Mammalian), By Service Type (Contract Manufacturing and Contract Research), By Product (Biologics and Biosimilars), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Biopharmaceutical CMO and CRO Market
Regional growth and demand
North America is expected to dominate the market during the forecast period in the Biopharmaceutical CMO and CRO market.
North America held the majority of the market share by revenue for the biopharmaceutical CMO and CRO market. The explanation for this situation exists because multiple service providers maintain operations in this area. The U.S. market currently has many approved products that CMOs are manufacturing at their facilities. Small- and mid-size biopharmaceutical entities (SMEs) face difficulty because they cannot afford to create facilities that have advanced operational capabilities. The U.S. market now sees SMEs and CMOs develop an interdependent relationship, which results in U.S. market supremacy.
Asia-Pacific is projected to grow the fastest during the forecast period in the biopharmaceutical CMO and CRO market.
Asia-Pacific is projected to grow the fastest during the forecast period in the biopharmaceutical CMO and CRO market. The biopharmaceutical CMO & CRO market in the Asia Pacific displays rapid growth, while the region becomes the fastest developing market for biopharmaceutical research and development and manufacturing activities. The combination of regulatory changes and infrastructure improvements, together with the availability of numerous potential study participants, drives the current growth. U.S. biopharma companies have begun to explore Asian markets for their pharmaceutical product development needs because of increasing research and development costs in their domestic market.
Ready to lead the Biopharmaceutical CMO and CRO Market?
Discover the regional trends and growth factors shaping the industry. We’re here to assist with expert, personalized data.
Call +1 303 800 4326 or Send us a message for a personalized consultation.
Top 10 Trends in the Biopharmaceutical CMO and CRO Market
- Growing Outsourcing of R&D and Manufacturing
- Rapid Expansion of Biologics and Complex Modalities
- Adoption of Advanced Technologies
- Integrated CDMO/CRO Service Models
- Market Consolidation and Mergers & Acquisitions
- Globalisation and Emerging Market Growth
- Focus on Biosimilars and Orphan Drugs
- Digital Transformation and Data-Driven Clinical Trials
- Quality, Compliance, and Regulatory Navigation
- Sustainability and Green Manufacturing Practices
- Outsourcing of R&D and Manufacturing Operations
Biopharma companies are increasingly outsourcing drug development and manufacturing to outside experts to help cut costs and speed up drug development. They use outside experts to handle their drug development and manufacturing needs because this approach helps them achieve cost savings and a faster drug development timeline, along with making them competitive in the market.
- Rapid Expansion of Biologics and Complex Modalities
The rising demand for biologic therapies that include monoclonal antibodies, cell and gene therapies and ATMPs drives CMO and CRO companies to make more investments.
- Adoption of Advanced Technologies
Biopharmaceutical companies implement advanced technologies that include single-use technologies and continuous manufacturing, artificial intelligence, machine learning and automation.
- Integrated CDMO/CRO Service Models
Mergers and acquisitions enable CMO and CRO companies to expand their operations and access new market opportunities.
- Market Consolidation and Mergers & Acquisitions
CMO and CRO companies expand their operations in Asia-Pacific, South America and other emerging markets because of the cost benefits these regions provide.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Biopharmaceutical CMO and CRO Market
Empower your strategic planning
Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the anti-venom market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.
Top 20 Companies Leading the Biopharmaceutical CMO and CRO Market
- Lonza Group AG
- Thermo Fisher Scientific
- Catalent
- Samsung Biologics
- WuXi Biologics
- Boehringer Ingelheim
- Charles River Laboratories International
- ICON plc
- Parexel International
- IQVIA
- Syneos Health
- Medpace Holdings
- Labcorp Drug Development
- Fujifilm Diosynth Biotechnologies
- AGC Biologics
- CMC Biologics
- Rentschler Biopharma
- ProBioGen
- Inno Biologics
- JRS Pharma
- Lonza Group AG
Headquarters: Basel, Switzerland
Lonza Group AG established its operations in 1897. The Swiss-based contract development and manufacturing organization provides complete manufacturing solutions for biologics, small molecules, and cell and gene therapy, and custom manufacturing across its more than 30 facilities located in Europe, North America and Asia, which are expected to generate approximately 6.9 billion dollars in revenue during 2024. The company expands its operational abilities through its capacity development initiatives, which include acquiring essential biologics facilities to develop advanced therapeutic solutions.
- Thermo Fisher
Headquarters: Waltham, Massachusetts, United States
It is a US-based life sciences company started in 1956, operates in more than 60 countries to deliver analytical instruments and laboratory equipment, Patheon CDMO services, and CRO solutions, while generating a combined operational revenue of about 42.9 billion dollars in 2024 through its drug development, clinical research, and manufacturing services.
- Catalent, Inc.
Headquarters: Florida, United States
Catalent, Inc., established in 2007, operates as a US company that delivers drug delivery solutions and advanced biologics and gene therapy manufacturing services and analytical testing and clinical services through its network of more than 50 international sites, which generated approximately $4.3 billion in 2024 revenue. Catalent supports a wide variety of products which include small molecules and biologics.
- WuXi Biologics (Cayman) Inc.
Headquarters: Wuxi, Jiangsu Province, China
The Chinese CRDMO company WuXi Biologics (Cayman) Inc., which was established in 2015, provides its global clients with integrated biologics discovery and development and manufacturing services, while generating $2.9 billion in revenue. The company maintains a global portfolio that includes integrated biologics projects, while its manufacturing operations continue to expand.
- Samsung Biologics Co., Ltd.
Headquarters: Songdo, Incheon, South Korea
Samsung Biologics Co., Ltd. (established 2011) is a South Korean CDMO providing high-volume biologics development and commercial manufacturing services (mAbs, ADCs, vaccines) with extensive facilities in Incheon, South Korea, and global partnerships with major pharmaceutical companies, achieving $3.3 billion revenue in 2024, with increasing capacity through multiple bioreactor plants.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Biopharmaceutical CMO and CRO Market
Are you ready to discover more about the Biopharmaceutical CMO and CRO Market?
The report provides an in-depth analysis of the leading companies operating in the global biopharmaceutical CMO and CRO market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardised format that includes
Company Profile
- Lonza Group AG
- Business Overview
- Company Snapshot
- Products Overview
- Company Market Share Analysis
- Company Coverage Portfolio
- Financial Analysis
- Recent Developments
- Merger and Acquisitions
- SWOT Analysis
- Thermo Fisher Scientific
- Catalent
- Samsung Biologics
- WuXi Biologics
- Boehringer Ingelheim
- Charles River Laboratories International
- ICON plc
- Parexel International
- IQVIA
- Syneos Health
- Medpace Holdings
- Labcorp Drug Development
- Fujifilm Diosynth Biotechnologies
- AGC Biologics
- CMC Biologics
- Rentschler Biopharma
- ProBioGen
- Inno Biologics
- JRS Pharma
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Biopharmaceutical CMO and CRO Market
Conclusion
The global biopharmaceutical CMO and CRO Market size is expected to grow at a compound annual growth rate (CAGR) of 6.1%, from USD 39.1 billion in 2024 to USD 74.99 billion by 2035. Global market expansion is fuelled by rising investments, the need for enhanced productivity & craft and technological advancements. North America is expected to dominate the market during the forecast period due to the availability of excellent infrastructure and a higher number of companies in the sector. Asia-Pacific is projected to grow the fastest during the forecast period due to its rapidly growing research & development and manufacturing facilities.
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI. Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?